Stories, Hal said, spread and evolve. They are iterative encodings with redundancy built by improvisers. A story can live in ink, song, or the slow consensus of people who swear they remember the same gate.
The code was never meant to be a name. It was a checksum, a dead‑end on a sheet of data that no one would ever read again. Until it wasn’t. EKDV-691
| Phase | Indication | Design | Estimated Enrollment | |-------|------------|--------|----------------------| | | IPF (monotherapy vs. standard‑of‑care) | Randomized, double‑blind, 48‑week; three arms (placebo, EKDV‑691 60 mg, EKDV‑691 60 mg + pirfenidone) | 300 | | Phase IIb/III | Systemic sclerosis‑associated interstitial lung disease (SSc‑ILD) | Adaptive seamless design; primary endpoint: change in FVC at week 52 | 250 | | Phase II | Desmoplastic pancreatic cancer (in combination with nab‑paclitaxel) | Open‑label, biomarker‑enriched (high DDR1 expression) | 80 | | Phase I/II | Chronic kidney disease (CKD) with tubulointerstitial fibrosis | Exploratory safety & PD | 60 | Stories, Hal said, spread and evolve
If it's an error or diagnostic code:
EKDV-691 first appeared on the scene one fateful evening, during a charity gala hosted by one of New Eden's most influential tech moguls. The event was attended by the city's elite, and it was there that EKDV-691 made their grand entrance. The code was never meant to be a name
